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Primary CNS lymphoma: latest 
updates and a 10-year monocenter 
experience
TO THE EDITOR: We read with great interest the paper 
by Qian and colleagues, which described advances in the 
treatment of newly diagnosed primary central nervous sys-
tem lymphomas (PCNSLs) [1]. The authors showed the in-
creasing PCNSL incidence rate and the possible correlation 
of this increase with the increasing number of immunosup-
pressed patients. This appealing issue was confirmed in a 
recently published paper that reported a current Swedish 
scenario in which the increasing trend was mostly observed 
among elderly individuals [2].
Qian and colleagues extensively analyzed the available 
treatment options, such as high-dose methotrexate (HD- 
MTX) alone or as a component of various MTX-based che-
motherapy regimens, whole-brain radiotherapy (WBRT), 
and surgery. We agree with the authors that HD-MTX 
should be included in the first-line therapy; according to 
our knowledge, however, the best available evidence sug-
gests that HD-MTX should be administered in association 
with high-dose cytarabine to improve both progression-free 
survival (PFS) and overall survival (OS), as previously sug-
gested [3].
An important goal of PCNSL treatment is survival pro-
longation with minimal toxicity, especially neurotoxicity. 
The first randomization of the phase II IELSG32 (the 
International Extranodal Lymphoma Study Group-32) trial 
was designed to determine whether rituximab and thiotepa 
could improve the efficacy of first-line treatment comprising 
HD-MTX plus HD-cytarabine (MATRix regimen). The com-
plete response (CR) rate among patients receiving HD-MTX 
plus HD-cytarabine (control arm, arm A) was 23%, com-
pared to 30% in the arm receiving rituximab (arm B) and 
49% in the arm receiving both rituximab and thiotepa (group 
C); here, a multivariate analysis confirmed an independent 
association between the induction arm and CR rate [4]. 
The recently published second randomization was designed 
to investigate the efficacy of WBRT or autologous stem-cell 
transplantation (ASCT) as a consolidation therapy after in-
duction for patients with chemosensitive PCNSL. Out of 
122 eligible patients, 118 were randomly assigned to receive 
WBRT (group D) or ASCT (group E); both strategies were 
effective and yielded significantly improved CR rates after 
induction, with 2-year PFS rates of 80% and 69%, re-
spectively [5]. As expected, hematological toxicity was more 
common in ASCT arm, while neuropsychological tests dem-
onstrated cognitive impairments in attention and executive 
functions among patients receiving WBRT [5]. 
ASCT was previously shown to be high effective as a con-
solidation therapy with manageable toxicity in phase II trials 
of patients with chemosensitive PCNSL patients; con-
sequently, an international phase III study is ongoing and 
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Table 2. Responses to treatment and outcomes.
N of Patients (%)
Early discontinuation because of PD or toxicity   5/20 (25)
CR after induction   5/15 (33.3)
ORR after induction 10/15 (66.7)
CR after consolidation   9/15 (60)
Consolidation strategy for 10 responders
   WBRT   7/10 (70)
   ASCT   3/10 (30)
Relapsed patients   4/10 (40)
Alive patients   6/20 (30)
Abbreviations: ASCT, autologous stem cell transplantation; CR, 
complete response; ORR, overall response rate; PD, progressive 
disease; WBRT, whole brain radiotherapy.
Table 1. Patients’ characteristics.
Characteristic N of Patients (%)
Age:median (range) 61.5 yr (39–76)
Gender
   Men   11/20 (55)
   Women     9/20 (45)
ECOG PS
   0–1     7/20 (35)
   ≥2   13/20 (65)
Elevated LDH   13/20 (65)
Deep lesions   13/20 (65)
IELSG score
   Low     4/20 (20)
   Intermediate   14/20 (70)
   High     2/20 (10)
Multiple lesions   12/20 (60)
Elevated B2M   10/20 (50)
HBV positive     2/20 (10)
Abbreviations: B2M, beta-2-microglobulin; LDH, lactate dehydro-
genase; PS, performance status.
Table 3. Treatment toxicity.
N of Patients (%)
Hematological toxicity 
   Neutropenia 20/20 (100)
      Grade 3–4 18/20 (90)
   Anemia 14/20 (70)
      Grade 3–4   7/20 (35)
   Thrombocytopenia 20/20 (100)
      Grade 3–4 15/20 (75)
Mucositis   8/20 (40)
   Grade 3–4   1/20 (5)
Neurotoxicity   5/20 (25)
   WBRT     4/5 (80)
Fatal infections   3/20 (15)
   Encephalitis   1/20 (5)
   Pneumonia   1/20 (5)
   Klebsiella KPC   1/20 (5)
Abbreviation: WBRT, whole-brain radiotherapy. 
will randomize patients to receive ASCT or conventional 
chemoimmunotherapy [6]. 
Because the outcomes of PCNSL are relatively worse than 
those of systemic DLBCL, novel agents are under investig-
ation. The Bruton tyrosine kinase inhibitor ibrutinib was re-
cently shown to be highly effective against relapsed/refractory 
PCNSL in a phase I trial [7]. Additionally, chimeric antigen 
receptor-modified T-cell therapy exhibited anti-tumor ac-
tivity against a heavily pre-treated DLBCL with CNS local-
ization [8].
We would also like to address the important topic of 
the treatment of elderly patients with PCNSL, who account 
for an important proportion of the total population of pa-
tients with PCNSL. The MATRix regimen is not applicable 
for patients ＞70 years old; additionally, WBRT is expected 
to cause significant neurotoxicity, and a recently reported 
study demonstrated no improvements in survival in the 
last decades [9]. A recent meta-analysis confirmed that treat-
ment with a combination of HD-MTX and alkylating agents 
such as procarbazine or temozolomide was associated with 
improved survival. Although WBRT may also improve sur-
vival, it is associated with a significant risk of early or late 
neurotoxicity; therefore, previous authors suggested avoid-
ing WBRT or using it only as a strategy for relapsed disease 
[10]. Among elderly patients with PCNSL, promising results 
and manageable toxicity were reported with HD-MTX when 
administered in association with rituximab, procarbazine, 
and lomustine (lomustine was omitted via protocol amend-
ment because of infectious complications); specifically, 38 
(35.5%) and 15 of 107 patients (14%) achieved a CR and 
PR, respectively, while the 2-year PFS and OS were 37.3% 
and 47%, respectively [11]. 
At our institution, we have worked for many years in 
the field of optimal PCNSL management and have retro-
spectively analyzed a consecutive series of 20 patients diag-
nosed and treated during the period from 2005 to 2016. 
Younger and more fit patients received HD-MTX with cytar-
abine either alone or in combination with rituximab with 
or without thiotepa (rituximab 375 mg/m2 days -5 and 0, 
MTX 3.5 g/m2 day 1, cytarabine 2 g/m2×2, days 2–3, thiotepa 
30 mg/m2 day 4; MATRix regimen) every 3 weeks for up 
to 4 cycles. Elderly and unfit patients received HD-MTX 
and temozolomide. Induction was followed by WBRT with 
a minimum dose of 36 Gy or ASCT as consolidation. 
Responses were assessed after the 2nd and 4th cycles accord-
ing to the 2005 IPCG Response Criteria [12]; toxicity was 
defined according to the NCI-CTCAE criteria after each 
course of treatment. PFS was measured from date of treat-
ment initiation to the date of relapse or progression requiring 
subsequent treatment, while OS was measured from the 
date of treatment initiation to the date of death. Statistical 
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Fig. 1. Progression-free survival (PFS) among primary central nervous 
system lymphoma (PCNSL) patients receiving ≥2 treatment cycles vs. 
those who underwent early discontinuation.
analyses were performed using MedCalc software, v2.0 
(MedCalc, Ostend, Belgium). Survival was analyzed using 
the Kaplan-Meier method and the global log-rank test.
The median age was 61.5 years; additionally, 13 of 20 
patients (65%) had an Eastern Cooperative Oncology Group 
Performance score of ≥2 and 4, 14, and 2 patients had 
low, intermediate, and high International Extranodal 
Lymphoma Study Group scores, respectively, as shown in 
Table 1. Five of 20 patients (25%) discontinued treatment 
early (after 1 cycle) because of disease progression or toxicity 
and were analyzed separately in survival curves. Fifteen 
patients received at least 2 courses of treatment; among 
them, 10 were responders (66.6%) and 5 (33.3%) achieved 
a CR, as reported in Table 2. Two patients older than 70 
years who received HD-MTX and temozolomide experi-
enced progressive disease (PD). Grade 3–4 hematological 
toxicity was reported in all cytarabine-treated cases, and 
fatal infections were observed in 3 of 20 patients (15%) 
as presented in Table 3. All 10 responders received WBRT 
(7 patients) or ASCT (3 patients) as consolidation; 3 patients 
receiving WBRT and 1 receiving ASCT exhibited improved 
responses from PR to CR. Neurotoxicity was reported in 
5 patients (4 received WBRT). The median PFS and OS 
improved among patients receiving at least 2 courses of 
treatment, compared to the early discontinuation group (12 
vs. 2 mo, P=0.03; 10 vs. 4 mo, P=0.01). In the first group, 
the estimated 5-year PFS (Fig. 1) and OS were 35% and 
38%, respectively. 
Our study had some limitations, most notably the retro-
spective study design and small sample size, although these 
were comparable to previously published experiences [13, 14]. 
Although our cohort of 20 patients could not adequately 
represent the general population, our 10-year experience 
may help to confirm the difficulties experienced in clinical 
daily practice regarding the adequate treatment for PCNSL 
because of issues related to age, diagnostic delays, and a 
poor performance status. In conclusion, the presented data 
have led us to confirm that the treatment outcomes in re-
al-life practice are somewhat different from those in clinical 
trials. We suggest that the optimal induction therapy should 
include HD-MTX, HD-cytarabine, rituximab, and thiotepa 
in younger and fit patients, while WBRT and ASCT are 
both effective as consolidation therapies. 
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Table 1. Lambda DNA was measured using SYTOX Green.
Acetate 
Lambda DNA 0 ng/mL 1 ng/mL 3 ng/mL 5 ng/mL
Mean SD Mean SD Mean SD Mean SD
  0 mM 4,278 386 166,649 14,119 403,841 58,468 576,097 42,468 
25 mM 4,344 445 164,181 14,809 419,319 51,839 576,772 68,383 
50 mM 4,466 547 157,233 10,602 423,093 40,819 579,226 85,789 
The linearity was unaffected by the addition of 25 or 50 mM acetate. No statistically significant difference was observed between the data with
and without acetate addition (N=6). 
Abbreviation: SD, standard deviation.
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Acetate moderately attenuates the 
generation of neutrophil extracellular 
traps 
TO THE EDITOR: It has been suggested that short-chain 
fatty acids (SCFAs) such as acetate, propionate, and butyrate, 
which are produced by the microbial fermentation of dietary 
fiber in the gut, exhibit several immunologic or metabolic 
effects. For example, SCFAs can modulate neutrophil migra-
tion [1, 2], induce the differentiation of regulatory T cells 
[3], and inhibit tumor necrosis factor- production from 
macrophages [4, 5].
Recently, Vieira et al. [6] reported that treatment with 
acetate accelerated the resolution of inflammation in ex-
perimental mouse models of gout. The effects of acetate 
were shown to be mediated by accelerated neutrophil apop-
tosis, enhanced efferocytosis, reduced nuclear factor-B ac-
tivity, and an enhanced production of anti-inflammatory 
mediators including interleukin-10, transforming growth 
factor-, and annexin A1.
Neutrophils exert their anti-microbial functions through 
the formation of neutrophil extracellular traps (NETs), the 
production of reactive oxygen species, and the secretion 
of several proteases such as elastase, lactoferrin, and lysozyme. 
NETs are composed of decondensed chromatin fibers coated 
with antimicrobial proteins such as myeloperoxidase, neu-
trophil elastase, and -defensin [7]. However, NETs contrib-
ute to organ damage including acute lung injury, thrombosis 
formation, autoimmune pathologies, metastasis of malignant 
tumors, and atherosclerosis [7]. In this study, we investigated 
the effects of acetate on the formation of NETs.
The following methods were utilized. Heparinized pe-
ripheral blood was collected from healthy volunteers after 
obtaining their written informed consent. Neutrophil sepa-
ration (＞90% purity) was performed as reported previously 
[8]. This study was approved by the Ethics Committee of 
Himeji Dokkyo University (12-01, 17-08).
Phorbol myristate acetate (PMA), bovine serum albumin, 
nuclease from Staphylococcus aureus, ethylene glycol tetra-
acetic acid, diphenylene iodonium (DPI), and acetate were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). SYTOX 
